Armistice Capital, Other Investors Show an Interest in Ocular Research
Tech

Armistice Capital, Other Investors Show an Interest in Ocular Research

While biotech research areas such as obesity drugs—which Morgan Stanley Research upped its 6-year market forecast for by $39 billion this year—have been a focus for institutional investors and hedge funds in recent years, a number have also participated in deals involving research that specifically addresses vision- and eye-related conditions.
by Carl Williams
Most Popular